touchENDOCRINOLOGY caught up with Dr Antonio Ceriello to discuss the European Steering Committee’s ‘A New Era in Diabetes Care’ report and what this means for patients with type 2 diabetes, chronic kidney disease and cardiovascular disease. For further information, please click here for the full report.
1. Please provide a brief overview of the aims of the European Steering Committee’s ‘A New Era in Diabetes Care’ report (0:06)
2. What differences exist in treatment guidelines across Europe and how can these be harmonised? (1:10)
3. What were the committee’s recommendations in terms of reviewing key performance indicators and treatment outcomes? (2:14)
4. What will be the next steps in developing a structured care plan for patients with type 2 diabetes, chronic kidney disease and cardiovascular disease? (3:27)
Speaker disclosure: Antonio Ceriello is on the advisory board for Abbott, BD, Eli Lilly, Mundipharma and Novo Nordisk. He has given lectures for Astra Zeneca, Berlin Chemie, Boehringer Ingelheim, Eli Lilly, Mundipharma, Novo Nordisk and Roche Diagnostics, and received research grants from Mitsubishi.
Support: Interview commissioned and filming supported by Touch Medical Media. Commissioned in liaison with Havas SO.
Published online: 3 July 2020
Related Videos In Diabetes
Dr Teresa Quattrin, EASD 2020 – Updates from the T1GER study
We spoke with Teresa Quattrin (University at Buffalo, Oishei Children’s Hospital) following her presentation of the T1GER study, which investigated the effect of treatment with golimumab in children, adolescents, and young adults with newly diagnosed type 1 diabetes. Disclosures: Tersea Quattrin discloses the following: Consultant to Janssen Research & Development Clinical Trial, Principal Investigator at […]
Prof. Hiddo Lambers Heerspink, EASD 2020 – Updates from the DAPA-CKD trial
touchENDOCRINOLOGY were delighted to speak with Prof. Hiddo Lambers Heerspink to hear more about the highly anticipated results of DAPA-CKD, investigating dapagliflozin in patients with chronic kidney disease with or without type 2 diabetes. Disclosures: Prof. Lambers Heerspink discloses the following: Grant Funding and Consultancy from AstraZeneca, Boehringer Ingelheim and AbbVie, Steering committee member for […]
Dr Ramzi Ajjan, EASD 2020 – Updates from the LIBERATES trial
We spoke with Dr Ramzi Ajjan (University of Leeds and Leeds Teaching Hospitals Trust) at Virtual EASD 2020 following the presentation of the results from the LIBERATES trial (improving gLucose control in patIents with diaBEtes following myocaRdial infArction: The role of a novEl glycaemic monitoring). Disclosures: Ramzi Ajjan has received institutional research grants from Abbott, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!